KNOWLEDGE BANK

Interviews

Digital Transformation in Pharma Manufacturing | David Holt, FactoryTalk | ISPE 2026 | Pharma Focus Asia

Group Executive Director, FactoryTalk
David Holt is the Group Managing Director at Factory Talk with extensive leadership experience across multiple industries He focuses on innovative software solutions that enable the digital transformation of operations within GxP pharmaceutical and medical deviceregulated industries

Articles

Redefining Therapeutics

Cancer immunotherapy has proven that removing inhibitory signals can generate durable tumor control yet it has also clarified the core limitation Many treatments do not fail because effector cells cannot recognise cancer but they fail because the local ecosystem enforces immune suppression and immune exclusion The tumor microenvironment contains regulatory T cells suppressive myeloid populations t...

Research Insights

Novel EDGE encoding method enhances ability to identify genetic interactions

Assumptions are made about the genetic model of single nucleotide polymorphisms SNPs when choosing a traditional genetic encoding additive dominant and recessive Furthermore SNPs across the genome are unlikely to demonstrate identical genetic models However running SNPSNP interaction analyses with every combination

Case Studies

Prescribing Antibiotics to ‘At-Risk’ Children With Influenza-Like Illness In Primary Care: A Qualitative Case Study

Abstract Objectives National Institute for Health and Care Excellence guidelines recommend immediate antibiotic treatment of respiratory tract infections in atrisk individuals with comorbidities Observational evidence suggests that influenza particularly predisposes children to bacterial comp

Techno Trends

New Exo-PDAC Assay Discovered for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC)

Biological Dynamics Inc discovered new ExoPDAC liquid biopsy assay for the early detection of pancreatic ductal adenocarcinoma PDAC in highrisk adults Globally pancreatic ductal adenocarcinoma PDAC is one of the most aggressive and lethal forms of cancer

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Computational Approach towards Designing Potent Inhibitors for Tuberculosis

Soumyadip Das

Soumyadip Das received a BSc degree from University of Calcutta, India, in 2017 and a MSc degree from Vellore Institute of Technology, Vellore, India, in 2019. He is currently pursuing his PhD degree from Vellore Institute of Technology, Vellore, India, under the supervision of Dr. Kaushik Chanda. His research interest includes diversity-oriented synthesis, anticancer drug design, and nanocatalysis.

 

Balamurali MM

Balamurali MM, was awarded the Master’s degree in Chemistry, by Madurai Kamaraj University, Tamil Nadu, India in 1999. He persuaded his doctoral research in Photophysical Chemistry at Indian Institute of Technology Kanpur, under the supervision of Prof. Sneh Kumar Dogra. In 2005, he was awarded the CSIR research associate fellowship and continued his postdoctoral research in Prof. Raghavan Varadarajan’s group at Indian Institute of Science Bangalore.

 

Kaushik Chanda

Kaushik Chanda, obtained his MSc in Organic Chemistry from Gauhati University, Assam India in 2001. Subsequently worked as a Senior Research Fellow in ICAR-NATP funded project in St Anthonys College, Shillong, India from 2002-2005. In 2006, he moved to Taiwan for pursuing PhD in Applied Chemistry from National Chiao Tung University under the guidance of Prof Chung Ming Sun on a topic of Combinatorial Chemistry.

 

2

Novel Claudin Targeted C-terminal Clostridium Perfringens Enterotoxin Conjugated Anticancer Nanotherapeutics

Sushil Y. Raut

Sushil Y. Raut Assistant Professor and Head of Research Promotion Cell, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune. He has over 12 years of teaching and research experience. He has more than 25 research and review publications. He filed 3 Indian patents and over 20 national as well as international presentations in his credits. He is recipient of international research mobility fellowship and other prestigious awards.

 

Tanaji D. Nandgude

Tanaji D. Nandgude, Associate Professor, Dr. D. Y. Patil institute of Pharmaceutical Sciences and Research, Pimpri, Pune. He has 15 years of experience in teaching and research in pharmacy. He has more than 50 research/review papers, more than 60 research paper presentations, 5 book publications and granted projects to his credit. He is recipient of “Young Researcher Award”.

 

3

Homeopathic Science

Aditya Dilipkumar Patil

Aditya Dilipkumar Patil pursed B.H.M.S. and MD (Hom) from Bharati Vidyapeeth (Deemed to be University) Homoeopathic Medical College and Post Graduate Research Centre, Pune. He is currently working as Assistant Professor in Department of Homoeopathic Pharmacy at Dr.D.Y.Patil Homoeopathic Medical College and Research Centre, Pimpri, Pune 411018. He is a member of Chandrabhaga Charitable trust since 2017 and Life member of Moredada Charitable Trust, Nashik, Department of Herbal Medicine since 2018. He was working as Senior Research Fellow in Central Council for Research in Homoepathy (CCRH under Ministry of AYUSH). His main research work focuses on Evidenced based medicine, Diabetes, preclinical studies (In-vitro & In-vivo), nanoparticle etc.

 

Parth Sanjeev Aphale

Parth Sanjeev Aphale pursed B.H.M.S. from Dhondumama Sathe Homoeopathic Medical College and Research Centre, Pune and MD (Hom) from Foster Development Homoeopathic Medical College, Aurangabad. He is currently working as Professor in Department of Homoeopathic pharmacy at Dr.D.Y.Patil Homoeopathic Medical College and Research Centre, Pimpri, Pune 411018.

 

Dharmendra Basudeo Sharma

Dharmendra Basudeo Sharma pursed B.H.M.S. from Dhondumama Sathe Homoeopathic Medical College and Research Centre, Pune and MD (Hom) from University of Rajasthan and Ph.D from Maharashtra University of Health Science (MUHS). He is currently working as Principal and Head of Institute at Dr.D.Y.Patil Homoeopathic Medical College and Research Centre, Pimpri, Pune 411018.

 

4

Labelling and imaging of Radiopharmaceuticals

Sumel Ashique

Sumel Ashique has been working as an assistant professor in Bengal College of Pharmaceutical Sciences & Research, Durgapur 713212, West Bengal, India. He has 3.5 years of teaching experience. He has achieved 50+ publications of International and national accredited reputed journals (Scopus, UGC). He has knowledge in drug delivery, nanotechnology and targeted treatment strategy. He has also 4 granted patents from IP and Australia, 8 published book chapters in International Books and 12 book chapters have been submitted to well-known publishers like Springer, Elsevier, Bentham and Taylor & Francis. Currently he is editing 5 books under CRC; AAP, Springer and Wiley publisher

 

Radheshyam Pal

Radheshyam Pal is an Assistant Professor at Pandaveswar School of Pharmacy. His areas of expertise in Neuropharmacology. He specifically works on the role of natural products in the CNS. He has 2 years of teaching experience. He has 2 patents and also 10 book chapters submitted in international publisher.

 

5

Government Investment in AI Capabilities will Cement Singapore’s Position as a Premier Clinical Trial Location

Edwin Ng

Edwin Ng joined Medidata in 2014 and heads the Life Science industry of Dassault Systemes across the Asia Pacific region. Under his leadership, the company’s regional business recorded significant year-on-year growth and achieved multiple leadership awards. Edwin has spent the last 27 years of his career managing enterprise solutions businesses.

 

press releasesRead more...

Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven Discovery

As AI accelerates recombinant protein and antibody discovery for therapeutic and diagnostic development access to wellcharacterized target proteins is essential for evaluating AIdesigned molecules Sino Biological Inc Shenzhen Stock Exchange SZ a global biotechnology company

Collaboration aims to accelerate development of next generation medicines

The Personalised Medicine Centre PMC a joint initiative between Murdoch University and the Perron Institute biotechnology company Syngenis Labs and the Perron Institute are collaborating to establish a specialised preclinical safety testing platform for RNAbased medicines designed to treat diseases...

ITM and AtomVie Global Radiopharma Enter Supply Agreement for n.c.a. Lutetium-177

ITM Isotope Technologies Munich SE ITM a leading radiopharmaceutical biotech company and AtomVie Global Radiopharma AtomVie a radiopharmaceutical contract development and manufacturing organization CDMO today announced a supply agreement

Evotec and Bristol Myers Squibb advance strategic protein degradation partnership with second IND acceptance

Evotec SE NASDAQ EVO Frankfurt Prime Standard EVT today announced that its strategic protein degradation partnership with Bristol Myers Squibb has received a second Investigational New Drug IND acceptance from the US Food

Introducing Cognizant® Patient Hub Operations: AI-enabled patient access offering designed to shorten the path from prescription to therapy

Cognizant Nasdaq CTSH today introduced Cognizant Patient Hub Operations an offering built on NVIDIA accelerated computing that pairs AI agents with healthcareexperienced specialists to support patients and help drive better access to therapy

Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production

Thermo Fisher Scientific the world leader in serving science today announced the Gibco VaxEvo CD Medium a chemically defined and animal originfree medium designed to support suspension HEK cell growth and hightiter adenovirus production

EventsRead more...

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

03 - 04

Dec 2026

LATEST NEWSRead more...

Bionsight Enters into Collaboration with Astellas to Develop Autoimmune Disorder Therapy

Bionsight has entered into a global research and development RD collaboration with Astellas Pharma to explore a potential firstinclass treatment for autoimmune disorders

Isomorphic Labs Enters into Collaboration with MSD for Cancer Drug Discovery

Isomorphic Labs has entered into a strategic research collaboration with MSD to discover smallmolecule drug candidates for an important oncology target

Sanofi Receives Approval for Infilbray to Treat Neurological Symptoms of Type 3 Gaucher Disease

Sanofi has received approval from the US Food and Drug Administration FDA for Infilbray venglustat an oral medicine for treating neurological manifestations of Type Gaucher disease GD in adults and children weighing at least kg

Pfizer Enters into Agreement with Starna Therapeutics for Autoimmune Disease Treatments

Pfizer has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics to develop RNAbased in vivo chimeric antigen receptor Tcell CART therapies for autoimmune diseases

OXB Partners with Aura Biosciences for Drug Manufacturing

OXB has confirmed a manufacturing and supply partnership with Aura Biosciences

GSK Receives Approval for Nelkarmi to Treat Advanced ALK-Positive Lung Cancer

GSK plc LSENYSE GSK has received accelerated approval from the US Food and Drug Administration FDA for Nelkarmi neladalkib a treatment for adults with locally advanced or metastatic anaplastic lymphoma kinase ALKpositive nonsmall cell lung cancer NSCLC